Kiora Pharmaceuticals Aktie

Kiora announced publication of the phase-1 study of KIO-301 in Nature Medicine. The open dose-escalation study with six subjects met the primary safety endpoint with no serious adverse events; ocular side effects were mild and transient. Exploratory data showed temporal fluctuations in light perception and light-induced activity in the visual cortex, and patients reported improvements in quality. Kiora has a liquid balance sheet but is burning cash quickly; a randomized phase-2 study (ABACUS-2) with higher doses has been initiated and analysts see upside to $12 per share given a market capitalization of $10.71 million. » Más en de.investing.com

Kiora Pharmaceuticals has completed a private placement raising up to $24 million in gross proceeds, consisting of a $5.0 million upfront payment and up to an additional $19 million upon exercise of milestone-based warrants. Sole investors are Perceptive Advisors and ADAR1 Capital Management; the securities were placed at-the-market and sold without a placement agent. The warrants are immediately exercisable at $1.94 and could generate about $19 million more if fully exercised. Kiora has a market capitalization of around $7.98 million, strong short-term liquidity (Current Ratio 5.99) and negative levered free cash flow of -$10.07 million over the last twelve months. » Más en de.investing.com

Kiora Pharmaceuticals posted a net loss of $10.8 million for fiscal 2025, after reporting a net profit of $3.6 million in the prior year. Cash and short-term investments totaled $17.1 million at year-end; cash flow from operating activities was an outflow of $10.0 million, and InvestingPro warns of high cash burn. R&D expenses rose to $10.8 million before reimbursements, and the company is treating patients in two phase-2 trials (KIO-301, KIO-104) with initial ABACUS-2 data expected in Q3 2027. Kiora has an option agreement with Senju for Asia worth up to $110 million and expects existing funds to finance operations through the end of 2027. » Más en de.investing.com